Predicting the outcome of melanoma: Can we tell the future of a patient's melanoma?

Oriol Yï¿½lamos; Pedram Gerami

doi:10.2217/MMT.15.15

Predicting the outcome of melanoma: Can we tell the future of a patient's melanoma?

Oriol Yï¿½lamos, Pedram Gerami^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Cutaneous melanoma is responsible for the greatest number of skin cancer related deaths. For many years there were few therapeutic options. However, in the last years a number of new therapeutic options have emerged showing improved survival rates for advanced melanoma patients. A significant question based on these findings is whether identification and treatment of patients with biologically aggressive melanomas at an earlier clinical stage offer an opportunity for even greater improvement in overall survival. In this review, we will discuss the recent advancements in molecular strategies beyond traditional staging to identify biologically aggressive melanomas, and which are their implications in terms of predicting the prognosis of patients with melanoma.

Original language	English (US)
Pages (from-to)	217-224
Number of pages	8
Journal	Melanoma Management
Volume	2
Issue number	3
DOIs	https://doi.org/10.2217/MMT.15.15
State	Published - Jan 1 2015

Keywords

Comparative genomic hybridization
FISH
Gene-expression profiling
Melanoma
Next-generation sequencing
Prognosis
Sentinel lymph node biopsy

ASJC Scopus subject areas

Oncology
Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/MMT.15.15

Cite this

@article{7a2538c7408448b5b0ae6e42c92aa6dc,

title = "Predicting the outcome of melanoma: Can we tell the future of a patient's melanoma?",

abstract = "Cutaneous melanoma is responsible for the greatest number of skin cancer related deaths. For many years there were few therapeutic options. However, in the last years a number of new therapeutic options have emerged showing improved survival rates for advanced melanoma patients. A significant question based on these findings is whether identification and treatment of patients with biologically aggressive melanomas at an earlier clinical stage offer an opportunity for even greater improvement in overall survival. In this review, we will discuss the recent advancements in molecular strategies beyond traditional staging to identify biologically aggressive melanomas, and which are their implications in terms of predicting the prognosis of patients with melanoma.",

keywords = "Comparative genomic hybridization, FISH, Gene-expression profiling, Melanoma, Next-generation sequencing, Prognosis, Sentinel lymph node biopsy",

author = "Oriol Y{\"i}¿½lamos and Pedram Gerami",

year = "2015",

month = jan,

day = "1",

doi = "10.2217/MMT.15.15",

language = "English (US)",

volume = "2",

pages = "217--224",

journal = "Melanoma Management",

issn = "2045-0885",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Predicting the outcome of melanoma

T2 - Can we tell the future of a patient's melanoma?

AU - Yï¿½lamos, Oriol

AU - Gerami, Pedram

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cutaneous melanoma is responsible for the greatest number of skin cancer related deaths. For many years there were few therapeutic options. However, in the last years a number of new therapeutic options have emerged showing improved survival rates for advanced melanoma patients. A significant question based on these findings is whether identification and treatment of patients with biologically aggressive melanomas at an earlier clinical stage offer an opportunity for even greater improvement in overall survival. In this review, we will discuss the recent advancements in molecular strategies beyond traditional staging to identify biologically aggressive melanomas, and which are their implications in terms of predicting the prognosis of patients with melanoma.

AB - Cutaneous melanoma is responsible for the greatest number of skin cancer related deaths. For many years there were few therapeutic options. However, in the last years a number of new therapeutic options have emerged showing improved survival rates for advanced melanoma patients. A significant question based on these findings is whether identification and treatment of patients with biologically aggressive melanomas at an earlier clinical stage offer an opportunity for even greater improvement in overall survival. In this review, we will discuss the recent advancements in molecular strategies beyond traditional staging to identify biologically aggressive melanomas, and which are their implications in terms of predicting the prognosis of patients with melanoma.

KW - Comparative genomic hybridization

KW - FISH

KW - Gene-expression profiling

KW - Melanoma

KW - Next-generation sequencing

KW - Prognosis

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85042391892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042391892&partnerID=8YFLogxK

U2 - 10.2217/MMT.15.15

DO - 10.2217/MMT.15.15

M3 - Review article

SN - 2045-0885

VL - 2

SP - 217

EP - 224

JO - Melanoma Management

JF - Melanoma Management

IS - 3

ER -

Predicting the outcome of melanoma: Can we tell the future of a patient's melanoma?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this